We found that the intermediate isolates not only showed increased DLX resistance, but also had enhanced resistance against three other DNA damaging agents, a different fluoroquinolone ciprofloxacin (CPX)25,26, the anti-cancer drug doxorubicin (DOXO)27 and the chemotherapeutic mitomycin C (MMC)28, compared to the hyper-sensitive recA::Tn mutant (Fig. 2A). The gene discussed is RAD51; the disease is cancer.